Bayer stock tests critical support as selling pressure mounts again
Bayer Stock Remains in Consolidation Phase
The recovery rally seen in mid-month appears to have fizzled out, serving only to close the downside gap from early in the month between €40.36 and €39.77.
100-Day Moving Average in Focus
Since last Wednesday, selling pressure has noticeably intensified. The recent exit of activist investor Inclusive Capital has added further downward momentum, pushing the stock toward another test of the 100-day moving average (SMA100). This same level had previously provided temporary support in early March, marking the starting point of the brief rebound.
A decisive break below this key moving average—which serves as a barometer for the medium-term trend—would be particularly significant. A subsequent drop below the monthly low of €35.20 would open the door to a deeper pullback toward the 200-day moving average (SMA200), currently at €32.52.
What's Next for Bayer Stock?
If, however, the stock finds support again at the SMA100, bulls may attempt another breakout above the long-term downtrend line near €47.86. To do so, the share price would first need to reclaim the €40.00 mark and surpass the monthly high of €40.52 just above it.
